News

Pfizer will end development of daily anti-obesity pill due to liver injury
Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient ...
Study identifies 3 strategies to minimize muscle loss from GLP-1 weight loss drugs
People taking GLP-1 drugs can decrease fat mass while minimizing muscle loss with a few key strategies that include proper ...
Managed Healthcare Executive14h
Liver Injury Ends Development of Pfizer’s Oral GLP-1 for Obesity
In one study, once-daily danuglipron resulted in one patient who experienced drug-related elevated liver enzymes.
Roche: Forget Tariffs And Focus On The Positives -- There Are Many
Roche's strong U.S. presence and diversified product portfolio may mitigate the impact of potential tariffs, making it a ...
Medscape3d
GLP-1s Eyed as Key to Managing T1D With Obesity
As obesity rates rise among individuals with T1D, GLP-1 agonist medications, indicated for T2D and weight loss, are ...
Viking Therapeutics draws Neutral rating at Goldman Sachs on competitive headwinds
Goldman Sachs launched its coverage of Viking Therapeutics (NASDAQ:VKTX) with a Neutral recommendation and a $30 per share target on Tuesday, arguing that competitive headwinds in the weight loss drug ...